These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 16729327)
1. Impact of obesity on treatment of chronic hepatitis C. Charlton MR; Pockros PJ; Harrison SA Hepatology; 2006 Jun; 43(6):1177-86. PubMed ID: 16729327 [TBL] [Abstract][Full Text] [Related]
2. Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans. Hu KQ; Currie SL; Shen H; Cheung RC; Ho SB; Bini EJ; McCracken JD; Morgan T; Bräu N; Schmidt WN; Jeffers L; Wright TL; Dig Dis Sci; 2007 Feb; 52(2):570-8. PubMed ID: 17226072 [TBL] [Abstract][Full Text] [Related]
3. [Metabolic syndrome in patients with chronic hepatitis C genotype 1]. Baĭzhanova ZhZh; Ignatova TM; Nekrasova TP; Abdurakhmanov DT Vestn Ross Akad Med Nauk; 2011; (1):3-7. PubMed ID: 21400720 [TBL] [Abstract][Full Text] [Related]
4. Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection. Hanouneh IA; Feldstein AE; Lopez R; Yerian L; Pillai A; Zein CO; Zein NN Clin Gastroenterol Hepatol; 2008 May; 6(5):584-9. PubMed ID: 18455698 [TBL] [Abstract][Full Text] [Related]
5. The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Lo Iacono O; Venezia G; Petta S; Mineo C; De Lisi S; Di Marco V; Rodolico V; Amato M; Ferraro D; Giordano C; Almasio PL; Craxí A Aliment Pharmacol Ther; 2007 May; 25(10):1181-91. PubMed ID: 17451564 [TBL] [Abstract][Full Text] [Related]
6. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Walsh MJ; Jonsson JR; Richardson MM; Lipka GM; Purdie DM; Clouston AD; Powell EE Gut; 2006 Apr; 55(4):529-35. PubMed ID: 16299039 [TBL] [Abstract][Full Text] [Related]
8. Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C. Negro F; Clément S J Viral Hepat; 2009 Oct; 16(10):681-8. PubMed ID: 19732324 [TBL] [Abstract][Full Text] [Related]
9. Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Lok AS; Everhart JE; Chung RT; Padmanabhan L; Greenson JK; Shiffman ML; Everson GT; Lindsay KL; Bonkovsky HL; Di Bisceglie AM; Lee WM; Morgan TR; Ghany MG; Morishima C; Clin Gastroenterol Hepatol; 2007 Feb; 5(2):245-54. PubMed ID: 17296533 [TBL] [Abstract][Full Text] [Related]
10. Treatment of chronic hepatitis C in patients with decompensated cirrhosis. Everson GT Rev Gastroenterol Disord; 2004; 4 Suppl 1():S31-8. PubMed ID: 15184823 [TBL] [Abstract][Full Text] [Related]
11. Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy. Hung CH; Kuo FY; Wang JH; Lu SN; Hu TH; Chen CH; Lee CM; Eng HL Antivir Ther; 2006; 11(4):483-9. PubMed ID: 16856622 [TBL] [Abstract][Full Text] [Related]
12. Fat, diabetes, and liver injury in chronic hepatitis C. Ratziu V; Trabut JB; Poynard T Curr Gastroenterol Rep; 2004 Feb; 6(1):22-9. PubMed ID: 14720450 [TBL] [Abstract][Full Text] [Related]
13. Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C. Saadoun D; Asselah T; Resche-Rigon M; Charlotte F; Bedossa P; Valla D; Piette JC; Marcellin P; Cacoub P Hepatology; 2006 Jun; 43(6):1337-45. PubMed ID: 16729318 [TBL] [Abstract][Full Text] [Related]
14. Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis. Fontana RJ; Everson GT; Tuteja S; Vargas HE; Shiffman ML Clin Gastroenterol Hepatol; 2004 Mar; 2(3):183-97. PubMed ID: 15017601 [No Abstract] [Full Text] [Related]
15. Hepatic steatosis and hepatitis C: Still unhappy bedfellows? Hwang SJ; Lee SD J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():96-101. PubMed ID: 21199519 [TBL] [Abstract][Full Text] [Related]
16. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease. Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634 [TBL] [Abstract][Full Text] [Related]
17. Impact of host insulin resistance on fibrosis and response to interferon in chronic hepatitis C. Moţa M; Popa S; Mota E; Diaconescu I; Gheorghiţoiu I; Panduru M Rom J Intern Med; 2008; 46(2):105-12. PubMed ID: 19284081 [TBL] [Abstract][Full Text] [Related]
18. [Metabolic syndrome and insulin resistance in patients with chronic hepatitis C]. Baĭzhanova ZhZh; Ignatova TM; Nekrasova TP Ter Arkh; 2010; 82(10):51-6. PubMed ID: 21341465 [TBL] [Abstract][Full Text] [Related]
19. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413 [TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis. Haga Y; Kanda T; Sasaki R; Nakamura M; Nakamoto S; Yokosuka O World J Gastroenterol; 2015 Dec; 21(46):12989-95. PubMed ID: 26675364 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]